Dr. Stephen Gillard

Dr. Stephen Gillard
Born in Nova Scotia and raised in Dedham, Dr. Gillard received his undergraduate degree from Saint Anselm College. He earned his medical degree from Georgetown University School of Medicine and did his surgical internship at UMass Memorial Medical Center in Worcester. He completed his training in urology at Lahey Hospital and Medical Center in Burlington. Dr. Gillard has been practicing urology in southeastern Massachusetts since 1998. He has held the position of Chief of Urology at Beth Israel Deaconess Hospital – Plymouth (formerly Jordan Hospital). In 2011, he joined Greater Boston Urology and now practices general urology at our Plymouth Care Center. He sub-specializes in enlarged prostate therapies, including Rezūm therapy. And in 2021, Dr. Gillard was designated as the first Massachusetts Center of Excellence for GreenLight™ Laser Therapy treatment – a minimally invasive outpatient procedure for men looking to treat their benign prostatic hyperplasia (BPH) Regularly named a "Top Doc," Dr. Gillard has experience as Chief of Surgery and Chief of Urology at his community hospital. He has also been trained in the SpaceOAR® Hydrogel system and is eager to educate patients on how this treatment option can help minimize the side effects of prostate cancer radiation therapy. Dr. Gillard is also a recognized kidney stone expert.
Medical School:

Georgetown University


Umass Memorial Medical Center


Lahey Hitchcock Clinic


Saint Anselm College

All surgical treatments have inherent and associated side effects. Individual’s outcomes may depend on a number of factors, including but not limited to patient characteristics, disease characteristics and/or surgeon experience. The most common side effects are mild and transient and may include mild pain or difficulty when urinating, discomfort in the pelvis, blood in the urine, inability to empty the bladder or a frequent and/or urgent need to urinate, and bladder or urinary tract infection. Other risks include ejaculatory dysfunction and a low risk of injury to the urethra or rectum where the devices gain access to the body for treatment. Further, there may be other risks as in other urological surgery, such as anesthesia risk or the risk of infection, including the potential transmission of blood borne pathogens. For more information about potential side effects and risks associated with Aquablation therapy for Benign Prostatic Hyperplasia (BPH) treatment, speak with your urologist or surgeon. Prior to using our products, please review the Instructions for Use, Operator’s Manual or User Manual, as applicable, and any accompanying documentation for a complete listing of indications, contraindications, warnings, precautions and potential adverse events. No claim is made that the AquaBeam Robotic System will cure any medical condition, or entirely eliminate the diseased entity. Repeated treatment or alternative therapies may sometimes be required.

Rx Only